Diabetes, Obesity and Metabolism

Aims & Scope

Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism.

The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction.

Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal.

Original research may be published as a main paper or as a research letter.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	5.7
2024	5.40

SJR (SCImago Journal Rank)

Year	Value
2024	2.251

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	162

Journal Rank

Year	Value
2024	1154

Journal Citation Indicator

Year	Value
2024	5731

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes

  Citation: 702

  Authors: H. J., D., L., B., J.

• Incretin hormones: Their role in health and disease

  Citation: 645

  Authors: Michael A., Juris J.

• Pancreatic β‐cell mass in European subjects with type 2 diabetes

  Citation: 633

  Authors: J., Y., R. M., C., J. C.

• Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension

  Citation: 607

  Authors: John P. H., Rachel L., Melanie, Luc F., Kristian, Katerina, Ildiko, Barbara M., Tugce Kalayci, Julio, Thomas A., Sean, Koutaro, Robert F.

• Hepatic steatosis: a role for <i>de novo</i> lipogenesis and the transcription factor SREBP‐1c

  Citation: 579

  Authors: P., F.

• An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines

  Citation: 531

  Authors: Nicholas M., Maarten W.

• Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

  Citation: 492

  Authors: K., W. T., K.‐A., M., K., C., W., G.

• Meta‐analysis: effect of hormone‐replacement therapy on components of the metabolic syndrome in postmenopausal women

  Citation: 489

  Authors: S. R., J. M. E., T. M., E., N. S., E. E.

• Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

  Citation: 481

  Authors: R., L., M., F., A., D. E., R. A., M., T., P.

• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

  Citation: 477

  Authors: M. A., G., D., L., P. P.

---